Ajinomoto (2802) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
30 Jun, 2026Corporate overview and global presence
Operates in 40 countries and regions with 121 subsidiaries and 126 production plants as of March 2026.
Employs 34,787 people, including over 1,700 in research and development.
Founded in 1909, with a legacy of innovation in amino acid science and umami discovery.
Purpose and sustainability goals
Aims to extend healthy life expectancy for 1 billion people and reduce environmental impact by 50%.
Focuses on creating shared value (ASV) through business activities that benefit society and the economy.
Pursues resilient, sustainable food systems and well-being for people, society, and the planet.
Business segments and performance
FY25 sales: ¥1,583.7 billion; business profit: ¥181.1 billion.
Main segments: seasonings/foods (59% of sales), frozen foods (18%), healthcare/others (11%).
Largest markets: Americas (36% of sales), Japan (22%), Asia (24%), EMEA (18%).
Latest events from Ajinomoto
- Sales up 7.7% with record profit, but net profit fell 12% on tax; guidance unchanged.2802
Q1 20259 Jul 2026 - Doubling medical food sales by 2030 through 20%+ growth, innovation, and global expansion.2802
Investor update8 Jul 2026 - AI-driven growth boosts ABF/ABF™ demand, margins, and capacity through innovation and investment.2802
Investor update3 Jul 2026 - Record sales and profit growth led to upward forecasts and increased shareholder returns.2802
Q2 20251 Jul 2026 - Record sales and profit highs, with raised full-year profit outlook and strong segment momentum.2802
Q3 202630 Jun 2026 - Record profit and sales growth achieved, with further gains targeted amid managed global risks.2802
Q4 202613 May 2026 - Integrated sustainability and agri-food innovation drive growth and aim to double key solution sales by 2030.2802
Investor Day 20266 May 2026 - Governance, compensation, and management reforms drive long-term growth and value creation.2802
Investor update9 Apr 2026 - Record sales and profit growth led by overseas, healthcare, and currency gains amid cost pressures.2802
Q3 20259 Jan 2026